STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
¿Qué tal es el rendimiento del precio de la acción STAA?
El precio actual de STAA es de $26.28, ha disminuido un 9.31% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de STAAR Surgical Co?
STAAR Surgical Co pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de STAAR Surgical Co?
La capitalización bursátil actual de STAAR Surgical Co es $1.3B
¿Es STAAR Surgical Co una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 11 analistas han realizado calificaciones de análisis para STAAR Surgical Co, incluyendo 0 fuerte compra, 0 compra, 11 mantener, 2 venta, y 0 fuerte venta